Han Lee becomes president and CFO of ImmPACT Bio
California, USA-based chimeric antigen receptor (CAR) T-cell therapies developer ImmPACT Bio has appointed Han Lee as president and chief financial officer (CFO).
An accomplished biotechnology executive, Dr Lee joins ImmPACT Bio with more than 10 years of corporate finance, strategy, business development, and company building experience in the biopharmaceutical industry. Dr Lee succeeds Vikram Lamba, who will support the transition to Dr Lee in the near term.
Prior to joining ImmPACT Bio, Dr Lee was CFO of Neogene where he led the financial operations and investor relations activities for the company and played an instrumental role in the acquisition of the firm by AstraZeneca (LSE: AZN) last November.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze